

## **SAFETY DATA SHEETS**

**This SDS packet was issued with item:**

078004341

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

074975272 076950877 078555236

**The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).**

078071864



A Pfizer Company

# SAFETY DATA SHEET

Revision date: 17-May-2018

Version: 2.0

Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Ciprofloxacin in 5% Dextrose Injection, USP (Hospira Inc.)

**Trade Name:** Not applicable

**Chemical Family:** Fluoroquinolone

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as antibiotic agent

### Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Hospira UK Limited  
Horizon  
Honey Lane  
Hurley

Maidenhead, SL6 6RJ  
United Kingdom

### Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

### Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

**GHS - Classification** Not classified as hazardous

### Label Elements

**Signal Word:** Not Classified

**Hazard Statements:** Not classified in accordance with international standards for workplace safety.

### Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
 (Hospira Inc.)  
 Revision date: 17-May-2018

Page 2 of 9

Version: 2.0

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Ciprofloxacin	85721-33-1	Not Listed	Aquatic Acute 2 (H401) Aquatic chronic 2 (H411)	< 1
Lactic acid	50-21-5	200-018-0	Eye Dam. 1 (H318) Skin Irrit. 2 (H315)	< 1
Hydrochloric Acid	7647-01-0	231-595-7	STOT SE 3 (H335) Skin Corr. 1A (H314) Press. Gas Acute Tox. 3 (H331)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Dextrose	14431-43-7	Not Listed	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	*

**Additional Information:**

\* Proprietary  
 \*\* to adjust pH  
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture**

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 3 of 9

Version: 2.0

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical product used as antibiotic agent

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

### Ciprofloxacin

Pfizer OEL TWA-8 Hr: 600µg/m<sup>3</sup>

### Hydrochloric Acid

ACGIH Ceiling Threshold Limit: 2 ppm

Australia PEAK 5 ppm

7.5 mg/m<sup>3</sup>

Austria OEL - MAKs 5 ppm

8 mg/m<sup>3</sup>

Belgium OEL - TWA 5 ppm

8 mg/m<sup>3</sup>

Bulgaria OEL - TWA 5 ppm

8.0 mg/m<sup>3</sup>

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 4 of 9

Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Cyprus OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Czech Republic OEL - TWA	8 mg/m <sup>3</sup>
Estonia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	2 ppm 3 mg/m <sup>3</sup>
Germany (DFG) - MAK	2 ppm 3.0 mg/m <sup>3</sup>
Greece OEL - TWA	5 ppm 7 mg/m <sup>3</sup>
Hungary OEL - TWA	8 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 ppm 8 mg/m <sup>3</sup>
Italy OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Japan - OELs - Ceilings	2 ppm 3.0 mg/m <sup>3</sup>
Latvia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Luxembourg OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Malta OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Netherlands OEL - TWA	8 mg/m <sup>3</sup>
Poland OEL - TWA	5 mg/m <sup>3</sup>
Portugal OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Romania OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Slovakia OEL - TWA	5 ppm 8.0 mg/m <sup>3</sup>
Slovenia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Spain OEL - TWA	5 ppm 7.6 mg/m <sup>3</sup>
Switzerland OEL - TWAs	2 ppm 3.0 mg/m <sup>3</sup>
Vietnam OEL - TWAs	5 mg/m <sup>3</sup>

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

##### Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 5 of 9

Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Solution	<b>Color:</b>	Clear, colorless to pale yellow
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

<b>Solvent Solubility:</b>	No data available
<b>Water Solubility:</b>	No data available
<b>Solubility:</b>	Soluble: Water
<b>pH:</b>	3.5 - 4.6
<b>Melting/Freezing Point (°C):</b>	No data available
<b>Boiling Point (°C):</b>	No data available.

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Ciprofloxacin**

Predicted 7.4 Log D -0.291

**Lactic acid**

No data available

**Dextrose**

No data available

**Water for injection**

No data available

**Hydrochloric Acid**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 6 of 9

Version: 2.0

### 10. STABILITY AND REACTIVITY

#### Possibility of Hazardous Reactions

**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

##### General Information:

The information included in this section describes the potential hazards of the individual ingredients.

##### Short Term:

Accidental ingestion may cause effects similar to those seen in clinical use.

##### Known Clinical Effects:

Quinolones may effect connective tissue structures. Tendonitis and tendon rupture have occurred as late as several months after quinolone treatment. The most common adverse reactions associated with the use of quinolones include gastrointestinal distress, such as nausea or diarrhea, and central nervous system (CNS) effects, including insomnia, dizziness, and seizures. Convulsion, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones. The most common adverse effects seen during clinical use of this drug include nausea, diarrhea, vomiting, abnormal liver function tests, increased eosinophils in blood or tissue (eosinophilia), headache, restlessness.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Ciprofloxacin

Rat Oral LD50 > 2000 mg/kg  
Rat IV LD 50 207mg/kg

##### Lactic acid

Rat Oral LD50 3543 mg/kg  
Rabbit Dermal LD50 > 2000 mg/kg

##### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Lactic acid

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Moderate Severe

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Ciprofloxacin

Reproductive & Fertility Rat Oral 100 mg/kg/day NOAEL No effects at maximum dose  
Reproductive & Fertility Rabbit Oral 35 mg/kg/day LOAEL Maternal Toxicity, Not Teratogenic

##### Lactic acid

Reproductive & Fertility Rat Oral 6.25 mg/kg/day NOEL Fertility, Not teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 7 of 9

Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

#### Ciprofloxacin

*In Vitro* Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

*In Vitro* Cell Transformation Assay Hamster Negative

*In Vitro* Forward Mutation Assay Mouse Lymphoma Positive

*In Vivo* Micronucleus Mouse Negative

*In Vivo* Dominant Lethal Assay Mouse Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### Hydrochloric Acid

IARC: Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

#### Toxicity:

##### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

#### Ciprofloxacin

*Pseudokirchneriella subcapitata* (Green Alga) OECD EC50 96 Hours 4.83 mg/L

*Brachydanio rerio* (Zebra fish) OECD EC50 72 Hours > 100 mg/L

*Daphnia Magna* (Water Flea) OECD EC50 48 Hours 65.3 mg/L

##### Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

#### Ciprofloxacin

*Lemna minor* (Common Duckweed) OECD 7 Day(s) EC50 3.75 mg/L Growth

#### Persistence and Degradability:

##### Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

#### Ciprofloxacin

OECD Activated sludge Ready 0% After 28 Day(s) Not Ready

#### Bio-accumulative Potential:

##### Partition Coefficient: (Method, pH, Endpoint, Value)

#### Ciprofloxacin

Predicted 7.4 Log D -0.291

**Mobility in Soil:** No data available



## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 8 of 9

Version: 2.0

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Ciprofloxacin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

#### Lactic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-018-0

#### Dextrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

#### Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg

## SAFETY DATA SHEET

Material Name: Ciprofloxacin in 5% Dextrose Injection, USP  
(Hospira Inc.)  
Revision date: 17-May-2018

Page 9 of 9

Version: 2.0

### 15. REGULATORY INFORMATION

CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	Schedule 6
	231-595-7

#### Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled  
Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life  
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects  
Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage  
Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation  
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage  
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 8 - Exposure Controls / Personal Protection.

**Revision date:** 17-May-2018  
Product Stewardship Hazard Communication

**Prepared by:** Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

## SECTION 1 - IDENTIFICATION

### Product Identifier

**Product Name:** EZ-Zyme® Enzymatic Cleaner

**Product Code:** 3-750, 3-755

### Recommended Use of the Chemical and Restrictions on Use

**Recommended Use:** A phosphate-free, multiple enzymes formula used for ultrasonic cleaning and soaking of surgical and dental instruments.

**Restrictions on Use:** Product is not a sterilizing agent. All instruments must be autoclaved after cleaning.

### Details of the Supplier

**Manufactured for:** Integra York PA, Inc.  
589 Davies Dr.  
York, PA 17402 USA  
1-866-854-8300

### Emergency Phone Number

**24-Hour Number:** 1-800-535-5053

**International:** 1-352-323-3500

## SECTION 2 – HAZARDS IDENTIFICATION

### Classification

Eye irritation, **Category 2B**; H320 - Causes eye irritation

### Label Elements

**Hazard Symbols(s):** None

**Signal Word(s):** Warning

**Hazard Statement(s):** Causes eye irritation.

**Precautionary Statements:** P305 + P351 + P338: **IF IN EYES:** Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

### Other Hazards

Not known.

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

## SECTION 3 – COMPOSITION / INFORMATION ON INGREDIENTS

<u>Common Name</u>	<u>CAS Number</u>	<u>Concentration, %</u>
Proprietary Enzyme Formula	***	100%

The specific chemical identity and exact percentage (concentration) of composition has been withheld as a trade secret in accordance with paragraph (i) of §1910.1200.

## SECTION 4 – FIRST AID MEASURES

### Emergency and First Aid Procedures

#### **Skin Exposure:**

May cause skin irritation. In case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove contaminated clothing and shoes. Cold water may be used. Wash clothing before reuse. Thoroughly clean shoes before reuse.

#### **Inhalation:**

If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

#### **Eye contact:**

Causes eye irritation. Check for and remove any contact lenses. Immediately flush eyes with running water for at least 15 minutes, keeping eyelids open. Cold water may be used. Get medical attention as needed.

#### **Ingestion:**

Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Medical conditions possibly aggravated by exposure:**

None.

#### **Notes to physician:**

Treat symptoms and eliminate overexposure.

## SECTION 5 – FIRE-FIGHTING MEASURES

### Fire Hazard Data

#### **Flash Point:**

>140° F, Nonflammable.

#### **Method Used:**

Closed cup

#### **Flammability Limits (vol/vol %):**

**Lower:** No Data

**Upper:** No Data

#### **Extinguishing Media:**

None.

#### **Special Fire Fighting Procedures:**

Nonflammable.

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

**Unusual Fire and Explosion Hazards:**

None.

**Hazardous Decomposition Materials (Under Fire Conditions):**

None.

## SECTION 6 – ACCIDENTAL RELEASE MEASURES

**Evacuation Procedures and Safety:**

None.

**Containment of Spill:**

Follow procedure described below under “Cleanup and Disposal of Spill” below.

**Cleanup and Disposal of Spill:**

Mop up any spilled product and discharge in accordance with local/regional/national/international environmental disposal regulations.

**Environmental and Regulatory Reporting:**

None.

## SECTION 7 – HANDLING AND STORAGE

**Minimum/Maximum Storage Temperatures:**

Store between 40° F and 120° F. Keep container closed when not in use.

**Handling:**

Avoid direct or prolonged contact with skin and eyes. If freezing occurs, thaw and remix before using. Frozen material may be thawed in a warm room. Avoid localized overheating. Vent drums while heating. Mix thoroughly to assure homogeneity.

**Storage:**

Store at room temperature. Store in tightly closed containers. Store in an area that is dry, well-ventilated; away from incompatible materials (see Section 10 • Stability and Reactivity).

## SECTION 8 – EXPOSURE CONTROL / PERSONAL PROTECTION

**Introductory Remarks:**

These recommendations provide general guidance for handling this product. Because specific work environments and material handling practices vary, safety procedures should be developed for each intended application. While developing safe handling procedures, do not overlook the need to clean equipment and piping systems for maintenance and repairs. Waste resulting from these procedures should be handled in accordance with Section 13 • Disposal Considerations. Assistance with selection, use and maintenance of worker protection equipment is generally available from equipment manufacturers.

**Exposure Guidelines:**

No exposure limits were found for this product or any of its ingredients.

**Engineering Controls:**

Where engineering controls are indicated by use conditions or a potential for excessive exposure exists, the following traditional exposure control techniques may be used to effectively minimize employee exposures: General area dilution/exhaust ventilation.

**Respiratory Protection:**

Not required for properly ventilated area.

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

**Eye/Face Protection:**

Recommended, but not required.

**Skin Protection:**

None required.

**Work Practice Controls:**

None required.

## SECTION 9 – PHYSICAL AND CHEMICAL PROPERTIES

**Physical Appearance:**

Dark amber brown clear liquid

**Odor:**

Characteristic scent

**Odor Threshold:**

Not determined

**pH:**

4.20 to 5.20

**Melting Point / Freezing Point Range:**

Not Available

**Initial Boiling Point and Boiling Range:**

100° C (212 F) at 760 mmHg

**Flash Point:**

>140° F. Closed cup

**Evaporation Rate:**

As water

**Flammability (solid, gas):**

Nonflammable

**Upper/Lower Flammability or Explosive Limits:**

Not Available

**Vapor Pressure:**

As water

**Vapor Density:**

1 (Air=1)

**Specific Gravity:**

1.03 to 1.10 at 20° C

**Water Solubility:**

Completely soluble

**Partition Coefficient (n-octanol/water):**

No data available.

**Auto-ignition temperature:**

No data available.

**Decomposition temperature:**

No data available.

**Percent Volatiles by Volume:**

Nonvolatile

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

**Viscosity:**  
Not available

## SECTION 10 – STABILITY AND REACTIVITY

**Reactivity:**

No data available.

**Chemical stability:**

This material is stable under normal handling and storage conditions described in Section 7.

**Possibility of hazardous reactions:**

Hazardous polymerization will not occur.

**Conditions to avoid:**

None

**Incompatible Materials:**

None

**Hazardous decomposition products:**

None

## SECTION 11 – TOXICOLOGICAL INFORMATION

### TOXICOLOGICAL INFORMATION (ANIMAL TOXICITY DATA)

**Acute Eye Irritation:**

**Toxicological Information and Interpretation:**

Eye - Mild eye irritation.

**Acute Skin Irritation:**

No test data found for product.

**Acute Dermal Toxicity:**

No test data found for product.

**Acute Respiratory Irritation:**

No test data found for product.

**Acute Inhalation Toxicity:**

No test data found for product.

**Acute Oral Toxicity:**

No test data found for product.

**Chronic Toxicity:**

This product does not contain any substances that are considered by OSHA, NTP, IARC or ACGIH to be "probable" or "suspected" human carcinogens. No additional test data found for product.

11.1.11 Aspiration hazard      No data

## SECTION 12 – ECOLOGICAL INFORMATION

**Ecotoxicological Information:**

No data found for product.

**Chemical Fate Information:**

# SAFETY DATA SHEET

Conforms with OSHA Hazard Communication Standard (29 CFR 1910.1200) HazCom 2012



Product: EZ-Zyme® Enzymatic Cleaner (REF 3-750, 3-755)

Revision Date: 03/23/2015

No data found for product.

## SECTION 13 – DISPOSAL CONSIDERATIONS

Dispose of in accordance with applicable municipal, provincial, state or national regulations. Not classified as dangerous according to transport regulations.

## SECTION 14 – TRANSPORT INFORMATION

Not classified as dangerous according to transport regulations.

## SECTION 15 – REGULATORY INFORMATION

### Inventory Status

UNITED STATES (TSCA)	Y
CANADA (DSL)	Y
EUROPE (EINECS/ELINCS)	Y
AUSTRALIA (AICS)	Y
JAPAN (MITI)	Y
SOUTH KOREA (KECL)	Y

Y = All ingredients are on the inventory.

E = All ingredients are on the inventory or exempt from listing.

P = One or more ingredients fall under the polymer exemption or are on the no longer polymer list. All other ingredients are on the inventory or exempt from listing.

N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing.

### Chemical Safety Assessment

No additional information available.

## SECTION 16 – OTHER INFORMATION

Issue Date: 03/16/2015

Revision Date: 03/16/2015

Liability Disclaimer: SDS information is provided based on OSHA's Hazardous Communication Regulation and for use of the persons required to receive this information under this regulation. The information is neither designed nor recommended for any other use or for use by any other person, including compliance with other laws. Integra York PA, Inc. (the "Company") does not warrant the suitability for use of this SDS for any other material or product not specifically identified herein. The Company does not warrant the accuracy or authenticity of this SDS unless it has been obtained directly from the Company, or posted or viewed on a Company website. This SDS is based on information that is believed to be reliable, but may be subject to change as new information becomes available. Because it is not possible to anticipate all conditions of use, additional safety precautions may be required. Since the use of this material is not under the Company's control, each user is responsible for making their own determination as to the safe and proper handling of this material in their own particular use of this material. The Company makes no representation or warranty, either expressed or implied, including as to merchantability or fitness for a particular purpose.